It's Time to Abandon an Upper Limit of Normal for Prostate Specific Antigen: Assessing the Risk of Prostate Cancer

No AccessJournal of UrologyEditorial1 Oct 2008It's Time to Abandon an Upper Limit of Normal for Prostate Specific Antigen: Assessing the Risk of Prostate Cancer Ian M. Thompson, Donna P. Ankerst, Ruth Etzioni, and Thomas Wang Ian M. ThompsonIan M. Thompson University of Texas Health Science Center at San Antonio, San Antonio, Texas Financial interest and/or other relationship with Mission Pharmacal, Johnson & Johnson and AstraZeneca. More articles by this author , Donna P. AnkerstDonna P. Ankerst University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author , Ruth EtzioniRuth Etzioni Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author , and Thomas WangThomas Wang Massachusetts General Hospital, Boston, Massachusetts More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2008.07.089AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail References 1 : Precipitating antigens of the normal human prostate. J Reprod Fertil1970; 22: 573. Google Scholar 2 : Clinical use of prostate specific antigen in patients with prostate cancer. J Urol1989; 142: 1011. Link, Google Scholar 3 : Cancer statistics, 2007. CA Cancer J Clin2007; 57: 43. Google Scholar 4 : Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials2000; 21: 251S. Google Scholar 5 : Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Section Rotterdam: A comparison of two rounds of screening. Eur Urol2007; 52: 89. Google Scholar 6 : Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med1991; 324: 1156. Google Scholar 7 : Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol1990; 143: 1146. Link, Google Scholar 8 : Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination: Enhancement of specificity with free PSA measurements. JAMA1997; 277: 1452. Google Scholar 9 : A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA1995; 273: 289. Google Scholar 10 : Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med2004; 350: 2239. Google Scholar 11 : Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA2005; 294: 66. Google Scholar 12 : Cancer mortality in the United States by education level and race. J Natl Cancer Inst2007; 99: 1384. Google Scholar 13 : Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst2007; 99: 1484. Google Scholar 14 : Risk factors for prostate cancer incidence and progression in the Health Professionals Follow-Up Study. Int J Cancer2007; 121: 1571. Google Scholar 15 : NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. V.2.2007. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I+Agree#detection. Accessed March 30, 2008.. Google Scholar 16 : Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values. J Urol1995; 154: 1795. Link, Google Scholar 17 : Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst2006; 98: 529. Google Scholar 18 : Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof#moreinfo. Accessed October 12, 2007.. Google Scholar 19 : External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology2006; 68: 1152. Google Scholar 20 : External validation of the prostate cancer risk calculator. J Urol2007; 177: 622. abstract 1874. Link, Google Scholar 21 : Comparison between the prostate cancer risk calculator and serum PSA. J Urol2007; 177: 624. abstract 1875. Google Scholar 22 : Influence of patient age on the serum PSA concentration: An important clinical observation. Urol Clin North Am1993; 20: 671. Google Scholar 23 : SEER Cancer Statistics Review, 1975-2004, National Cancer Institute, Bethesda, Maryland. http://seer.cancer.gov/csr/1975_2004. Accessed June 18, 2008.. Google Scholar 24 : http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp?sitearea=PED. Accessed March 30, 2008.. Google Scholar 25 : Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention: Cancer Prevent Res 2008; Online First 2008. http://cancerpreventionresearch.aacrjournals.org/cgi/rapidpdf/1940-6207.CAPR-08-0078v1. Accessed June 18, 2008.. Google Scholar 26 : Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology2005; 66: 356. Google Scholar 27 : 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA2005; 293: 2095. Google Scholar 28 : Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?. Curr Urol Rep2007; 8: 341. Google Scholar © 2008 by American Urological AssociationFiguresReferencesRelatedDetails Volume 180Issue 4October 2008Page: 1219-1222 Advertisement Copyright & Permissions© 2008 by American Urological AssociationMetricsAuthor Information Ian M. Thompson University of Texas Health Science Center at San Antonio, San Antonio, Texas Financial interest and/or other relationship with Mission Pharmacal, Johnson & Johnson and AstraZeneca. More articles by this author Donna P. Ankerst University of Texas Health Science Center at San Antonio, San Antonio, Texas More articles by this author Ruth Etzioni Fred Hutchinson Cancer Research Center, Seattle, Washington More articles by this author Thomas Wang Massachusetts General Hospital, Boston, Massachusetts More articles by this author Expand All Advertisement PDF downloadLoading ...